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Introduction
Breast cancer frequently metastasizes to the skeleton. It 
is estimated that 85% of individuals with advanced 
disease harbor bone metastases [1]. While ductal 
carcinoma  in situ detected early is 98% curable, bone 
metastases are basically incurable [2]. Metastatic cancer 
cells tend to colonize the heavily vascularized areas of the 
skeleton, such as the red marrow of the long bones, 
sternum, pelvis, ribs and vertebrae, where they disrupt 
not only bone physiology but also hematopoiesis and the 
immune system [3].
Metastases leading to overall bone loss are classiﬁ  ed as 
osteolytic. Th  ose leading to excess bone deposition are 
considered osteoblastic. However, both bone degradation 
and deposition likely occur early in the metastatic 
process. Th  e majority of breast cancer metastases ulti-
mately cause bone loss. Th  e clinical outcomes of bone 
pain, pathologic fractures, nerve compression syndrome, 
and metabolic disturbances leading to hypercalcemia and 
acid/base imbalance severely reduce the quality of life [3].
In the 1960s and 70s  it was proposed that bone 
degradation might result from the physical pressure of 
the tumor on the bone and/or direct resorption of the 
bone by tumor cells. It was also noted that tumor cells 
caused other cells in the bone (for example, lymphocytes) 
to produce molecules such as prostaglandins (PGs) that 
can aﬀ   ect bone [4]. While there is evidence that the 
breast cancer cell matrix metalloproteinases (MMPs) can 
resorb bone in vitro and contribute to bone degradation 
in vivo [5], it is now well accepted that osteoclasts are 
largely responsible for osteolytic metastatic lesions [6].
Bone remodeling
Bone provides support and protects vital organs but also 
is a metabolically active tissue. It is a reservoir of 
numerous growth factors as well as calcium and phos-
phorous, which are released from the matrix during bone 
remodeling. Cortical bone provides strength and 
protection while trabecular bone is the most metaboli-
cally active. Trabecular bone is the major site of bone 
turnover under normal conditions and in diseases of 
bone loss or formation.
Th  e skeleton is constantly undergoing remodeling. 
Even in adults it is estimated that about 10% of the bone 
is renewed each year [7]. Th   e normal processes of bone 
resorption and formation are remarkably well balanced. 
In the young adult, bone mass reaches its peak, but with 
increasing age there is a slow loss of mass. Th   is loss is 
more precipitous in women, due to the decrease in 
estrogen at menopause [3]. However, the presence of 
metastatic breast cancer cells or other bone metastatic 
cancers, such as prostate, lung, renal, and myeloma, 
accelerates the remodeling process and disturbs the 
balance between bone depositing cells, osteoblasts, and 
bone degrading cells, osteoclasts. It is impossible to 
understand the growth and progression of cancer cells 
in the bone marrow without consideration of the 
interaction between osteoblasts and osteoclasts. A 
thorough review of bone remodeling is beyond the 
scope of this article, and there are several excellent, 
recent reviews [8,9]. However, the process is described 
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osteolytic metastasis.
Bone remodeling is often described as a cycle begin-
ning with bone degradation and ending with bone 
deposition (Figure 1A). Th   is process is eﬀ  ected by osteo-
blasts and osteoclasts within a functional and anatomic 
unit known as the basic multicellular unit (BMU). Cells 
of the osteoblast lineage are derived from mesenchymal 
stem cells, and are represented in this unit by osteoblasts, 
bone lining cells and osteocytes. Bone lining cells appear 
microscopically as relatively undiﬀ   erentiated cells that 
line the bone. Th   eir function is not clear except that their 
retraction is necessary for bone resorption to begin [10]. 
Osteocytes are terminally diﬀ  erentiated osteoblasts that 
Figure 1. The bone microenvironment. (A) The bone microenvironment under conditions of normal bone remodeling; (B) and in the presence 
of osteolytic bone metastases. (A) The bone remodeling unit consists of osteoblasts, which produce osteoid, bone matrix, and osteoclasts, which 
degrade mineralized bone. Osteoblasts derive from mesenchymal stem cells in the marrow under control of Runx2, a key osteoblastic transcription 
factor. Osteoclasts derive from mononuclear myeloid precursors that fuse to form pre-osteoclasts. Under the infl  uence of macrophage colony-
stimulating factor (M-CSF) and RANKL (receptor activator for NFκB ligand) produced by osteoblasts and other cells in the microenvironment, 
pre-osteoclasts diff  erentiate into multinuclear, activated osteoclasts that adhere to the bone and begin matrix degradation. Osteoblasts also 
produce osteoprotegerin (OPG), a decoy receptor to RANKL. The ratio of RANKL to OPG determines the extent of the osteoclast activity and 
bone degradation. Other cells of the osteoblastic lineage include bone lining cells and osteocytes. (B) Metastatic breast cancer cells in the bone 
microenvironment secrete parathyroid hormone-related protein (PTHrP), cytokines and growth factors that negatively impact osteoblast function. 
RANKL and other pro-osteoclastogenic cytokines are increased with a concomitant reduction in OPG, resulting in more osteoclast formation and 
bone degradation. Osteoblast diff  erentiation is suppressed; new osteoid production is no longer able to keep pace with bone resorption. Current 
therapeutic targets are indicated in green. Bisphosphonates binding to hydroxyapatite are ingested by osteoclasts and cause their apoptosis. These 
drugs may also cause cancer cell death; however, they may also negatively aff  ect osteoblasts. Denosumab is an antibody directed to RANKL that 
prevents osteoclast diff  erentiation. Teriparatide is a recombinant peptide of parathyroid hormone that stimulates osteoblast activity and bone 
formation. In addition, pre-clinical trials with agents that target cathepsin K, certain matrix metalloproteinases (MMPs), and transforming growth 
factor (TGF)-β are underway. IGF, insulin-like growth factor; MCP-1, monocyte chemotactic protein-1; PDGF, platelet-derived growth factor; VEGF, 
vascular endothelial growth factor.
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deposition phase of remodeling. Once osteoblasts ﬁ  nish 
bone deposition, they undergo apoptosis, remain in the 
matrix as osteocytes or revert to thin bone-lining cells.
Osteoclasts derive from hematopoietic stem cells. Cells 
of the monocyte-macrophage lineage are stimulated to 
form osteoclast progenitor cells. Th   ese cells fuse to form 
multinucleated, but non-functional pre-osteoclasts. 
Further stimulation results in large multinuclear cells 
capable of bone resorption.
What initiates remodeling in the non-tumor-containing 
bone? Th   ere are many suspected factors, such as 
microfractures, loss of mechanical loading, hormones, 
cytokines, calcium levels and inﬂ  ammation. Osteocytes 
may act as mechanosensing cells and initiate the process 
when microfractures and loading are involved. In the 
context of the current discussion, cancer cells may 
initiate the process. Th   e resorption phase of the process 
begins with recruitment of pre-osteoclasts that diﬀ  eren-
tiate into activated osteoclasts under the direction of 
osteoblasts (Figure 1A). Osteoblasts produce macrophage 
colony stimulating factor (M-CSF) and receptor activator 
of NFκB ligand (RANKL), which bind to their respective 
receptors, c-fms and RANK, on pre-osteoclasts to bring 
about osteoclast diﬀ   erentiation and activation. Osteo-
blasts also produce osteoprotegerin (OPG), a decoy 
receptor to RANKL that curtails osteoclast activation. 
Th   us, the ratio of RANKL to OPG is critical for osteoclast 
activation. Once activated the large multinucleated 
osteo  clasts attach to the bone surface creating a 
resorption lacuna, a sealed zone in which acid and 
proteolytic enzymes, such as cathepsin K, are released 
and degrade the bone matrix. Th   is area has been likened 
to an extracellular lysosome [11]. Th   e osteoclasts work as 
part of the bone remodeling compartment, underneath a 
canopy of bone lining cells. In the next step, pre-
osteoblasts are recruited from the mesenchymal stem cell 
population and diﬀ  erentiate into osteoblasts. Th  ey  follow 
the osteoclasts, reforming the bone matrix. Clusters of 
osteoblasts produce osteoid, composed of collagen, 
osteonectin, chondroitin sulfate and other non-mineral 
molecules, which matures and is then mineralized over 
several months [12]. Th  is remarkable process of bone 
degradation and formation is synchronized by direct cell 
contact and a variety of secreted factors (Table 1). Th  e 
presence of tumor cells in the bone microenvironment 
perturbs the balance between osteoblasts and osteoclasts, 
leading to excess bone loss or formation. Here we discuss 
some of the proposed mechanisms that contribute to 
metastatic breast cancer-induced bone loss.
Osteoclasts and the vicious cycle model of bone loss
Th  e entry of breast cancer cells into the bone micro-
environment synergistically increases the complexity of 
cell-cell interactions. A working model to describe the 
bone remodeling compartment in the presence of 
metastatic cancer cells has been referred to as the ‘vicious 
cycle of bone metastasis’ [13] (Figure 1B). Th   ere are many 
excellent reviews describing this paradigm [14-17] from 
its inception in the 1990s. Th   e minimal essential compo-
nents are osteoblasts, osteoclasts, tumor cells and the 
mineralized bone matrix. According to this paradigm, 
the tumor cells produce a variety of growth factors, most 
notably parathyroid hormone-related protein (PTHrP) 
[18]. Th   e role of PTHrP in bone metabolism is not fully 
understood, but it is known to cause upregulation of 
RANKL and downregulation of OPG [19], thus enhan-
cing osteoclast function leading to bone degradation. In 
the process, growth factors stored in the matrix, such as 
transforming growth factor (TGF)-β, vascular endothelial 
growth factor (VEGF), insulin-like growth factors (IGFs), 
bone morphogenic proteins and ﬁ  broblast-derived 
factors, as well as calcium, are released into the bone 
micro environment.  Th   ese factors can stimulate the 
tumor cells to proliferate and produce more growth 
factors and more PTHrP, further perpetuating the vicious 
cycle of bone metastasis.
In reality the system is much more complex (Table 1). 
Cytokines such as IL-6, IL-8 and IL-11 secreted by breast 
cancer cells also promote osteoclast diﬀ  erentiation and 
bone resorption. IL-11, normally produced by bone 
marrow stromal cells and osteoblasts, is an important 
regulator of hematopoiesis and a potent promoter of 
osteo  clast formation. In addition, its expression is 
enhanced in the presence of TGF-β [20]. IL-8, a pro-
inﬂ  ammatory CXC chemokine, is secreted by monocytes, 
endothelial cells and osteoblasts. It can activate 
osteoclasts independent of RANKL [21]. Cancer cells 
also can elicit an increase in osteoblast production of 
several other osteoclastogenic cytokines, such as mono-
cyte chemotactic protein-1 (MCP-1) and IL-6, IL-8 and 
TNF [22].
TGF-β is well-known for its role in osteolytic bone 
metastasis. It can activate both Smad-dependent and 
Smad-independent signal pathways to induce pre-
osteolytic factors such as PTHrP [23]. Because of its 
signiﬁ  cant role, TGF-β has been a tempting therapeutic 
target. Ganapathy and colleagues [24] found that TGF-β 
antagonists are able to reduce bone metastasis and the 
number and activity of diﬀ   erentiated osteoclasts [24]. 
However, because TGF-β plays a more global role in cell 
proliferation and diﬀ  erentiation, its utility as a thera  peu-
tic may be limited.
The importance of osteoblasts in osteolytic breast 
cancer metastasis
Just as osteoblasts are a critical partner in normal bone 
remodeling, they are vital to the metastatic osteolytic 
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OPG, they are major mediators of osteoclastogenesis 
[25]. Current therapies consist of blocking osteoclast 
activity as a means of disrupting the vicious cycle. 
Bisphosphonates such as zoledronic acid (ZoledronateTM) 
bind to hydroxyapatite of the bone matrix and are 
ingested by osteoclasts, which then undergo apoptosis. 
However, this approach has not entirely solved the 
problem. Administration of bisphosphonates may slow 
osteolytic lesion progression and stabilize or increase 
overall bone density, but does not bring about healing 
[1,16,26]. Th   ere is evidence in both humans and animals 
that bone loss in osteolytic metastasis is partly due to the 
failure of the osteoblasts to produce new osteoid for the 
bone matrix.
Th  e hypoactivity of osteoblasts has been known for 
some time in multiple myeloma. Th  is is a disease of 
clonal malignancy of terminally diﬀ  erentiated  plasma 
cells that accumulate in the bone marrow. It is estimated 
that osteolytic lesions occur in 60 to 95% of myeloma 
patients [1,27]. In advanced disease, bone formation is 
essentially absent, and the processes of bone resorption 
and formation become uncoupled. Myeloma cells 
produce factors that upregulate osteoblast production of 
M-CSF and RANKL and downregulate production of 
OPG. Myeloma cells may also produce RANKL and 
directly aﬀ  ect osteoclasts [28]. Th   e mechanisms for sup-
pressed osteoblast activity are not clear but Dickkopf-1 
(DKK1), an inhibitor of Wnt signaling, is believed to 
inhibit osteoblast diﬀ  erentiation [29]. Other molecules 
made by multiple myeloma cells, such as IL-3, IL-7 and 
soluble frizzle-related protein-2, also inhibit osteoblast 
diﬀ  erentiation [27]. Furthermore, Pozzi and colleagues 
[30] have recently reported that high doses of zoledronic 
acid, the current standard therapeutic for most osteolytic 
diseases, may also negatively aﬀ  ect  osteoblast 
diﬀ   er en tiation.
Recently, we have found that metastatic breast cancer 
cells have profound eﬀ  ects on osteoblasts in culture [22] 
and in animals [31,32]. Metastatic breast cancer cells or 
their conditioned media increase osteoblast apoptosis, 
and suppress osteoblast diﬀ  erentiation and expression of 
proteins required for new bone matrix formation. 
Neutralization of TGF-β in conditioned medium from 
Table 1. Factors in the metastatic bone microenvironment that eff  ect osteolysis
Factor Source  Target  Eff  ect on target  Reference
PTH Serum  OB   RANKL  [41]
PTHrP CC  OB   RANKL  [13]
COX-2/PGE2  OB, CC  OB, CC   RANKL; in CC,  MMPs [46,47]
IL-1  Macrophages, monocytes, CC  OB   RANKL  [41]
IL-11 OB  OB   RANKL  [20]
TNFα Macrophages,  EC OB   RANKL  [41]
IGF Serum  OB   RANKL  [41]
FGF Stromal  cells  OB   RANKL  [41]
TGF-β  OB, CC, matrix release  OB, CC  In OB,  COX-2, cytokines; in CC,  PTHrP   [20]
PDGF  OC, CC, platelets, megakaryocytes  OB   OB proliferation; OB diff  erentiation; OB adhesion  [58,59]
Vitamin D/calcium  Serum  OB   RANKL if defi  cient   [66,67]
Estrogen  Serum  OB, OC  In OB,  OPG production,  collagen synthesis,  cytokines,  [63,64]
      apoptosis; in OC,  apoptosis
RANKL OB  OC   Osteoclastogenesis  [13]
OPG OB  OC   Osteoclastogenesis  [13]
IL-6 OB,  CC  OC   Osteoclastogenesis  [31]
IL-8  OB, CC, EC, monocytes  OC   OC activation  [21]
M-CSF OB,CC  OC   Osteoclastogenesis  [64]
MCP-1 OB,  CC  OC   Osteoclastogenesis  [22]
VEGF  OB, CC, EC  OC   OC formation  [48]
MMPs  OB, CC, EC  Matrix  Matrix degradation  [5]
Cathepsin K  OC  Matrix  Matrix degradation  [51]
Up arrows indicate increase; down arrows indicate decrease. CC, cancer cell; EC, endothelial cell; FGF, fi  broblast growth factor; IGF, insulin-like growth factor; MCP, 
monocyte chemotactic protein; M-CSF, macrophage colony-stimulating factor; MMP, matrix metalloproteinase; OB, osteoblast; OC, osteoclast; OPG, osteoprotegerin; 
PDGF, platelet-derived growth factor; PG, prostaglandin; PTH, parathyroid hormone; PTHrP, parathyroid hormone-related protein; RANK, receptor activator for NFκB; 
RANKL, receptor activator for NFκB ligand; TGF, transforming growth factor; VEGF, vascular endothelial growth factor.
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permitted the diﬀ   erentiation of osteoblasts in culture, 
suggesting that TGF-β negatively aﬀ  ects  osteoblasts 
while promoting growth of the metastatic cells [33]. In 
the presence of cancer cells, osteoblasts increase 
expression of pro-inﬂ  ammatory cytokines such as IL-6, 
monocyte chemotactic protein-1 (MCP-1), macrophage 
inﬂ   ammatory protein-2 (MIP-2; GRO alpha human), 
keratinocyte chemoattractant (KC; IL-8 human) and 
VEGF. Th  ese molecules not only help support tumor 
cells, but also are osteoclastogenic. When the bone loss is 
extensive, the osteoblasts are absent from the lesion [32]. 
Th   us, in the course of the osteolytic process, the osteo-
blasts are unable to fulﬁ  ll their role as bone building cells.
Breast cancer is often compared with prostate cancer, 
which metastasizes to the skeleton with a similar 
frequency. In contrast to breast cancer, prostate bone 
metastasis often results in osteoblastic lesions. While the 
outcome is predominantly osteoblastic, it is known that 
prostate cancer lesions display both blastic and lytic 
characteristics early in the process. Th   ere is evidence that 
osteoblastic metastases form at sites of osteolytic lesions, 
suggesting an overall increase of bone remodeling 
Accelerated osteoblastogenesis can be stimulated by 
factors secreted by prostate cancer cells, such as 
endothelin-1, TGF-β, and ﬁ  broblast growth factor (FGF) 
[1]. Th   ese molecules cause osteoblasts not only to form 
new bone but also to release RANKL and other 
osteoclastic mediators. Although the mechanisms of 
osteo  teoblastic and osteolytic responses are not fully 
understood, it is clear that many factors involved in 
osteolytic breast cancer bone metastasis also regulate the 
osteolytic aspects of prostate cancer. Akech and colleagues 
[34] recently reported that Runx2 (Runt-related trans-
crip  tion factor 2) is produced by the highly metastatic 
prostate cancer cell PC-3, and positively correlates to the 
severity of osteolytic disease. Th   ere is also evidence that 
molecules in conditioned medium from PC-3 cells alone 
[34], or from both PC-3 cells and MC3T3-E1 osteoblasts 
[35], promote osteoclastogenesis. While some of the 
growth factors produced by breast and prostate cancers 
may be diﬀ  erent, ultimately they engage the bone re-
modeling process.
Th   e bone remodeling microenvironment is a complex 
system in which the cell functions are controlled by 
multifunctional transcription factors, cytokines and 
growth factors. Th  e dynamics of this system are inter-
rupted when metastatic breast cancer cells are intro-
duced, adding another layer of active molecules to the 
bone environment. In the section that follows, we will 
discuss in greater detail the key factors involved in 
metastatic breast cancer osteolysis. While they are 
categorized into functional groups, it should be noted 
that many of these factors are multifunctional and must 
be considered within the context of the bone remodeling 
system as a whole.
Cancer cell survival in the bone microenvironment
Osteomimicry
It has been suggested that cancer cells preferentially 
metastasize to bone due to their ability to express genes 
that are normally considered bone or bone-related [36]. 
In doing so, cancer cells are equipped to home, adhere, 
survive and proliferate in the bone microenvironment. 
Osteomimetic factors include osteopontin (OPN), 
osteocalcin, osteonectin, bone sialoprotein, RANKL and 
PTHrP. Several of these molecules are related to the 
recruitment and diﬀ  erentiation of osteoclasts; some are 
prominent players in the vicious cycle. For example, OPN 
is produced by many breast cancer cells and has a strong 
clinical correlation with poor prognosis and decreased 
survival [37]. It can contribute to tumor cell survival, 
proliferation, adhesion, and migration. In the bone, OPN 
is involved in the diﬀ   erentiation and activity of 
osteoclasts, and inhibition of mineral deposition in the 
osteoid [37]. Th   e results of an in vivo study showed that 
OPN-deﬁ  cient mice showed signiﬁ  cantly reduced bone 
metastasis [38].
Runx2 expression
Interestingly, many osteomimetic factors are regulated by 
the same transcription factor, Runx2, considered to be 
the major regulator of osteoblast commitment and diﬀ  er-
entiation [39]. It is required to drive mesenchymal cells to 
become osteoblasts. Dysfunctional Runx2 results in the 
developmental arrest of osteoblasts and inhibition of 
osteo  genesis. Runx2 downregulates proliferation and 
induces p21, RANKL, MMP2, MMP9, MMP13, VEGF, 
OPN, bone sialoprotein and PTHrP protein expression to 
promote osteoblast diﬀ   erentiation, bone development 
and turnover [39].
It has also been suggested that Runx2 is ectopically 
expressed in bone-destined metastatic breast cancer 
cells. Evidence from an intratibial bone metastasis model 
indicates that when highly aggressive metastatic MDA-
MB-231 cells express dysfunctional Runx2 or small hair-
pin RNA for Runx2, both osteoclastogenesis and osteo-
lytic lesions decrease [40]. Th   ese results signify an impor-
tant role for cancer cell-derived Runx2 in the osteo  lytic 
process. Recent research has revealed how cancer cell 
Runx2 aﬀ  ects other cells in the bone micro  environment 
and promotes osteolysis. Pratap and colleagues [40] 
found that Runx2 responds to TGF-β stimulation by 
activating the expression of Indian hedgehog (IHH), 
which further increases the level of PTHrP. Th  us,  Runx2 
plays a signiﬁ  cant role in the vicious cycle via TGF-β-
induced IHH-PTHrP pathways in breast cancer cells, 
resulting in increased osteoclastogenesis and osteolysis.
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RANKL clearly holds the key to the osteolytic process. In 
fact, a new drug, denosumab (ProliaTM), a fully human 
monoclonal antibody to RANKL, has been approved by 
the US Food and Drug Administration (FDA) for the 
treatment of postmenopausal women with high risk of 
osteoporotic fractures, and is under priority review for 
patients with bone metastases. Osteoblasts and bone 
stromal cells can respond to a variety of substances that 
upregulate RANKL. PTH/PTHrP, TNF-α, prostaglandins 
(PGE2), IL-1, IL-11, FGF-2, and IGF-1 have been 
reported to increase RANKL production. Cells of the 
immune system, T cells and dendritic cells can also 
express RANKL. In this context, RANKL increases in the 
presence of inﬂ  ammatory agents from infectious organ-
isms, such as lipopolysaccharide, CpGpDNA and viral 
double-stranded DNA [41]. Several of these RANKL 
inducers merit further discussion with respect to meta-
static breast cancer-induced osteolysis.
Parathyroid hormone-related protein
PTHrP, one of many proteins controlled by Runx2, is a 
major eﬀ   ector in breast cancer bone metastasis pro-
gression and bone loss. It is common to ﬁ  nd increased 
PTHrP serum levels in breast cancer patients. PTHrP is 
expressed in the primary tumors of about 50% of patients 
and in more than 90% of breast cancer bone metastasis 
samples [18]. In the late 1980s, PTHrP was linked to 
hypercalcemia in several cancers, providing evidence that 
PTHrP was involved in bone resorption. Guise [18] 
demon  strated that increasing the expression of PTHrP in 
cancer cells enhanced osteolytic lesions in vivo, while 
decreasing the expression reduced the number and size 
of lesions. However, PTHrP does not directly stimulate 
osteoclast diﬀ   erentiation, but rather stimulates other 
cells to increase RANKL and decrease OPG production. 
In addition, factors such as TGF-β and IGFs that are 
released from the bone matrix during degradation serve 
to increase PTHrP expression in breast cancer cells. All 
in all, PTHrP is an important mediator between breast 
cancer cells and cells of the bone microenvironment and, 
as such, is a major contributor to the bone degradation 
process.
COX-2 and prostaglandins
Th   e cyclooxygenase enzymes COX-1 and COX-2 catalyze 
the conversion of arachidonic acid to prostaglandins and 
thromboxanes. While COX-1 is constitutively expressed 
in most tissues, COX-2 expression appears to be limited 
to brain, kidney, bone, reproductive organs and some 
neoplasms. PGs produced from this arachidonic acid 
conversion are both autocrine and paracrine factors that 
help to govern physiologic homeostasis. Of the many 
prosta  glandins, PGE2 is known to play a critical role in 
cancer progression. PGE2 is associated with inﬂ  am  ma-
tion, cell growth, tumor development and metastasis [42].
In the early 1970s it was reported that prostaglandins 
could resorb fetal bone in culture [43], and that aspirin, a 
COX-1 inhibitor, and indomethacin, a COX-2 inhibitor, 
could prevent osteolysis in tissue culture [44]. Th  ese 
ﬁ  ndings led to a ﬂ  urry of studies to develop COX and 
prostaglandin inhibitors as cures for bone metastasis. It is 
now known that PGE2 signaling through its receptor EP4 
plays a crucial role in osteolysis by inducing mono  cytes to 
form mature osteoclasts. In a series of in vitro, ex vivo and 
in vivo experiments, Ohshiba and colleagues [45] demon-
strated that direct cell-cell contact between breast cancer 
cells and osteoblasts caused an increase in COX-2 expres-
sion in the osteoblasts due to activation of the NFκB/
mitogen-activated protein (MAP) kinase pathway. Th  is 
increase in COX-2 results in increased secretion of PGE2, 
which binds to EP4 receptors on the surface of the 
osteoblasts. Th   e receptor binding activity in turn causes an 
increase in production of RANKL. Th  e PGE2-mediated 
pro  duc  tion of RANKL induces osteo  clasto  genesis via RANK.
NF-κB/MAP-kinase inhibitors (SN50, PD98059 and 
SB203580), COX-2 inhibitors (indomethacin) and EP4 
receptor decoy [46] all result in a down-regulation of 
RANKL production and a concomitant decrease in 
osteo  clastogenesis. COX-2 activity in breast cancer cells 
has also been found to modulate the expression and 
activity of MMPs. In the highly metastatic, COX-2-
expressing breast cancer cell line Hs578T, treatment with 
the selective COX-2 inhibitor Ns-398 markedly decreased 
the production of MMP1, 2, 3, and 13 in a dose-
dependent manner. COX-2 inhibition also partially 
attenu  ated the ability of two breast cancer cell lines to 
degrade and invade extracellular matrix components 
such as laminin and collagen [47].
Extracellular matrix metalloproteinase inducer
A newly discovered molecule downstream of RANKL is 
extra  cellular matrix metalloproteinase inducer (EMMPRIN)/
CD147, a cell surface glycoprotein that is known to induce 
MMPs and VEGF [48]. While EMMPRIN is produced 
normally during tissue remodeling, it increases during 
tumor progression and metastasis. Th  is molecule is also 
produced by metastatic breast cancer cells [49]. Increased 
production of EMMPRIN in turn leads to increases in 
VEGF and MMPs. Both RANKL and VEGF can induce 
osteoclast formation [48], and MMPs play a role in bone 
matrix degradation.
Extracellular matrix degradation and released 
matrix factors
Matrix metalloproteinases/cathepsin K
Th  e MMPs are considered to be important in the bone 
metastatic process. In a recent comprehensive review 
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regulators’ of the vicious cycle. As might be expected 
from the nature of the osteolytic process, that is, the 
degradation of bone, the microenvironment contains 
many proteases. Among these are the MMPs. Th  e  MMP 
family, composed of more than 20 members, can 
collectively degrade all components of the extracelluar 
matrix. Nevertheless, they do not appear to function in 
the osteoclast resorption lacuna, probably due to the low 
pH in this compartment. Cathepsin K is believed to be 
the major protease in this capacity. However, the MMPs 
may be involved in matrix remodeling once the 
osteoclasts are ﬁ   nished. Orr and colleagues [5] have 
determined MMPs suﬃ   cient to resorb bone in vitro and 
to contribute to the process in vivo. Matrix degradation 
appears to be only one of the roles of MMPs. Th  ey  also 
are regulators of other molecules important in the vicious 
cycle. Kang and colleagues [20] found that expression of 
two MMP genes, MMP1 and ADAMTS1, discriminated 
between a subline of osteotropic metastatic MDA-
MB-231 cells and the parental line.
Where do the MMPs come from? Cancer cells, 
osteoblasts, osteoclasts and endothelial cells produce 
MMPs. In addition, other cells not speciﬁ  c for bone but 
likely to be found in the bone (macrophages, neutrophils 
and T lymphocytes) produce MMPs. As pointed out by 
Lynch, the spatial and temporal expression of these 
molecules is of utmost importance. Th  is information is 
not easily obtained with in vitro studies.
Cathepsin K is the major mediator of bone resorption, 
controlling the osteoclast portion of the vicious cycle. It 
has high aﬃ   nity for type I collagen, the most abundant 
matrix protein. However, cathepsin K is also produced by 
other cells in the bone microenvironment, such as 
macrophages and bone marrow stromal cells. One of its 
substrates is SPARC (secreted protein acidic and rich in 
cysteine; osteonectin/BM-40) [51]. Proteolytic cleavage 
of SPARC releases biologically active cleavage products 
that aﬀ  ect angiogenesis factors such as VEGF, platelet-
derived growth factor (PDGF) and FGF-2. SPARC 
cleavage also coincides with an increase in inﬂ  ammatory 
cytokines such as IL-6 and IL-8 [51]. Th   us, cathepsin K is 
a key molecule not only in osteoclastic breakdown of 
collagen but also in angiogenesis and production of pro-
inﬂ  ammatory cytokines.
Transforming growth factor-β/insulin-like growth factors/
vascular endothelial growth factor
At least three major growth factors sequestered in the 
matrix are activated by MMPs. TGF-β is one of the most 
prominent. Several MMPs (MMP2, 3, 9) can release 
TGF-β from the latent state, allowing it to become active. 
Active TGF-β is involved in tumor growth, osteoblast 
retraction from the bone surface, inhibition of osteoblast 
diﬀ  erentiation [52,53] and promotion of osteoclast diﬀ  er-
entiation. Another growth factor sequestered in the 
matrix is IGF. IGF binding proteins keep this molecule 
latent. MMP1, 2, 3 process the binding factors and free 
IGF, allowing it to bind to its receptors found both on 
osteoblasts and osteoclasts. IGF binding initiates produc-
tion of M-CSF and RANKL by osteoblasts and c-fms and 
RANK by osteoclasts [54]. VEGF also forms a complex 
with the extracellular matrix [31,55]. MMP-9 is impor-
tant in the cascade leading to activation of VEGFA. Studies 
with MMP9-null mice indicate its importance in tumor 
progression in ovarian cancer, prostate cancer and bone 
metastasis [56]. While the case for the importance of 
MMPs as metastasis regulators is strong, they them  selves 
are regulated by tissue inhibitors of metallo  protein  ase 
(TIMPs). Furthermore, the molecules activa  ted by MMPs 
also have counter molecules creating a network of 
accelerators and decelerators centered around MMPs.
Osteoblast and osteoclast diff  erentiation factors
Platelet-derived growth factor
PDGF is a dimeric protein consisting of two of four 
possible subunits. It binds to two class III tyrosine kinase 
receptors, PDGFRα and PDGFRβ, leading to activation of 
several signaling molecules. PDGF can function as a 
mitogen for cells of mesenchymal origin and possesses 
chemoattractant properties, making it an important 
factor in cell proliferation and migration. At the tissue 
level, PDGF is involved in bone formation, wound 
healing, erythropoiesis and angiogenesis as well as tumor 
growth and lesion development [57].
In normal bone remodeling, osteoclasts secrete PDGF, 
which acts as a chemoattractant to recruit pre-osteoblasts 
to the site of bone repair [58]. Many metastatic breast 
cancer cell lines have been found to also secrete PDGF, 
which has a strong impact on osteoblast development. In 
a study by Mercer and Mastro [59], osteoblasts treated 
with conditioned media from MDA-MB-231 breast 
cancer cells displayed disorganized F-actin ﬁ  brils  and 
reduced focal adhesion plaques. When treated with 
neutralizing antibody to PDGF, the osteoblasts assumed 
normal morphology. In addition, PDGF has been shown 
to inhibit osteoblast diﬀ   erentiation [60], making it an 
important factor in bone remodeling and the osteolytic 
bone metastasis.
Placental growth factor
Placental growth factor is a VEGF homologue that binds 
to the VEGF receptor VEGFR-1. It promotes growth and 
survival of tumor cells [61], and is also involved in 
osteoclast diﬀ  erentiation. Th   e use of blocking antibodies 
to placental growth factor in two xenograft mouse/
human models greatly decreased the numbers and size of 
osteolytic lesions [61]. Surprisingly, this treatment did 
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thought to be inhibition of tumor cell adhesion as well as 
osteoclast diﬀ  erentiation.
In summary, all of these factors contribute to propa  ga-
ting the vicious cycle and increasing osteolysis (Figure 1B). 
Osteomimetic factors driven by abnormal Runx2 
activation in breast cancer cells may increase their 
survival in the bone microenvironment. Runx2 also 
promotes PTHrP expression in breast cancer cells, which 
in turn stimulates other cells, such as osteoblasts, to 
produce more RANKL, leading to further osteoclast 
activation. Meanwhile, COX-2 produced by breast cancer 
cells and osteoblasts increases the localized PGE2 
concentration, which can directly bind to osteoblasts, 
promoting RANKL expression and further stimulating 
osteoclast diﬀ  erentiation. Once osteoclasts are activated, 
they degrade bone matrix through several proteolytic 
enzymes, including MMPs and cathepsin K. Although 
cathepsin K is the major bone resorbing protease, MMPs, 
which are secreted by many cells, may be the ‘master 
regulator’ of the entire mechanism. Th  eir  multi-
functionality demonstrates their importance. MMPs are 
involved in the bone remodeling process after osteoclasts 
are ﬁ  nished. Th   ey activate latent molecules released from 
the matrix. At least three essential molecules, TGF-β, 
IGF, and VEGF, need to be activated by MMPs before 
they can function. Th   ese functional molecules complete 
the cycle and osteolysis continues. It should be noted that 
in addition to obvious members of the vicious cycle, 
other factors are produced during the process, including 
inﬂ  ammatory cytokines, which signiﬁ  cantly aﬀ  ect tumor 
cell survival, cell diﬀ  erentiation, and angiogenesis.
Physiological states that exacerbate osteolysis
While not directly responsible for osteolysis in metastatic 
breast cancer disease, there are physiological parameters 
that can amplify the degree of bone loss. Clinical studies 
of newly diagnosed breast cancer patients have revealed 
that high bone turnover correlates with a higher risk of 
skeletal complications [62]. For post-menopausal women, 
high bone turnover may be caused by estrogen deﬁ  ciency. 
Estrogen profoundly aﬀ   ects bone remodeling by 
suppressing production of RANKL while increasing 
production of OPG. Estrogen also increases osteoblast 
pro-collagen synthesis and decreases osteoblast apoptosis 
[63]. In addition, production of inﬂ  ammatory cytokines 
(that is, IL-6, TNF-α, M-CSF, IL-1) is suppressed by 
estrogen [64]. Estrogen has also been shown to promote 
osteoclast apoptosis and inhibit activation of mature 
osteo  clasts. Unfortunately, some of the therapies used for 
breast cancer patients may exacerbate the problem. For 
example, the use of aromatase inhibitors increases the 
risk for osteoporosis. Chemotherapy may bring about 
ovarian failure and premature menopause [1].
As primary constituents in bone metabolism, calcium 
and vitamin D can not be overlooked as critical regulators 
of osteolysis in bone metastatic breast cancer. In middle 
aged and elderly women, calcium and/or vitamin D 
deﬁ   ciencies are quite common, as is the incidence of 
breast cancer [65]. Epidemiological studies have also 
correlated the increase in breast cancer rates with 
decreasing sunlight exposure. It was recently reported 
that mice deﬁ   cient in vitamin D or calcium showed 
increased metastatic tumor growth and accelerated rates 
of bone resorption [66,67]. In light of these ﬁ  ndings, 
correction of calcium and vitamin D deﬁ  ciencies should 
be considered as adjuvant therapies in slowing or 
preventing osteolysis in breast cancer patients.
Chronic inﬂ  ammation has long been considered a risk 
factor in cancer initiation [68]. Inﬂ  ammation associated 
with bone fractures and arthritic joints has been 
anecdotally associated with the appearance of bone 
metastasis, often many years after the primary tumor has 
been treated. Recently, Roy and colleagues [69] investi-
gated this association in a mouse model of autoimmune 
arthritis and found that arthritic mice had an increase in 
both lung and bone metastasis compared to the non-
arthritic mice. Th  us,  inﬂ   ammation is likely to be 
important in cancer initiation, metastasis and the 
resulting osteolysis.
Breaking the vicious cycle
Understanding the mechanisms of osteolysis should be 
the key to designing the cure. Of course, the best cure for 
bone metastasis is prevention. Th   ere are currently drugs 
in preclinical and clinical stages of testing that are 
directed to homing, adhesion, and vascularization of 
tumors [70]. However, once bone metastasis has occur-
red, the aim has been to break the osteolytic cycle by 
targeting osteoclasts. Drugs of the bisphosphonate family 
have been used for many years as the standard of care. 
Until recently they were the only FDA approved drugs for 
metastatic bone disease [71]. Th  ese molecules bind to 
hydroxyapatite of the bone matrix and are ingested by 
osteoclasts, which then undergo apoptosis. Th  ere is 
evidence that bisphosphonates also contribute to tumor 
cell death, especially in combination with chemotherapy 
[72]. Th  ere are conﬂ  icting reports regarding their eﬀ  ect 
on osteoblasts. At higher doses they may in fact prevent 
osteoblast diﬀ  erentiation [30]. Of the bisphosphonates, 
zoledronic acid is the most potent. Clinical evidence 
indicates that this drug can reduce the rate of bone loss, 
but is not curative. It improves the quality of life by 
preventing fractures but does not prolong life [73]. 
Denosumab (ProliaTM), the latest drug to enter the ﬁ  eld, is 
a monoclonal antibody to RANKL. It inhibits the 
diﬀ  erentiation of osteoclasts by competitive binding with 
RANKL. Stopeck [74] recently reported the results of a 
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superior to zoledronic acid in preventing skeletal-related 
events in breast, prostate and multiple myeloma patients. 
Denosumab has recently been approved by the FDA for 
treatment of osteoporosis in women with high risk of 
fractures and is being considered for treatment of bone 
metastasis. However, both drugs are associated with low 
incidence of osteonecrosis of the jaw [75]. Another drug, 
teriparatide (ForteoTM), the amino-terminal 34 amino 
acids of parathyroid hormone, has been used for many 
years to treat osteoporosis. Teriparatide, in contrast to 
bisphosphonates and denosumab, acts on osteoblasts to 
stimulate bone formation. At ﬁ  rst glance it would seem 
ideal to pair bisphosphonates or denosumab with 
teriparatide since the former two block bone resorption 
and the latter stimulates bone deposition. However, 
teriparatide is associated with an increased risk of 
osteosarcoma and exacerbation of skeletal metastases 
because of its eﬀ  ect on bone turnover [75]. Other drugs 
on the horizon target TGF-β, and cathepsin K. Various 
approaches, including kinase inhibitors, ligand-neutral-
izing antibodies and anti-sense molecules, are being 
investigated [33].
Conclusions and the future
Most breast cancer metastasis to bone results in 
osteolytic lesions. Despite the role of the osteoclasts in 
this process, the outcome is due in large part to the 
impact of cancer cells directly and indirectly on osteo-
blasts. Induction of aberrant osteoclastogenesis is only 
part of the equation. Breast cancer cells also cause 
inhibition of osteoblast diﬀ   erentiation and adhesion, 
downregulation of collagen synthesis and increased 
osteoblast apoptosis. Th  us, bone loss is the result of 
excessive bone degradation and insuﬃ   cient bone replace-
ment. In the ﬁ  nal stages of metastatic osteolytic breast 
cancer disease, the cancer cells, fueled by growth factors 
released from the degraded matrix, expand unchecked. 
Eventually, bone remodeling ceases as both osteoblasts 
and osteoclasts are lost.
What can be done to stop osteolytic metastasis? To 
date, osteoclasts have been the primary target of drug 
therapies. Current treatments can improve bone density, 
decrease skeletal related events and ease bone pain, yet 
existing bone lesions do not heal. While drugs that 
inhibit osteoclast diﬀ  erentiation or activity are vital to 
treating osteolysis, therapies designed to restore osteo-
blast number and function will be required to fully 
resolve osteolytic lesions. Part of this uncertainty is 
because we do not fully understand all of the cell, cyto-
kine and growth factor interactions that occur in the 
bone microenvironment.
Identiﬁ  cation of a stimulator or protector of osteoblasts 
would be a major improvement in treatment for 
osteolytic breast cancer as well as other diseases of bone 
loss. However, there is no guarantee that inhibition of 
osteolytic lesions would prevent the growth of cancer 
cells in the bone or their spread to other organs. It is 
interesting that cancer cells often remain dormant in 
bone for many years before they begin to grow. 
Continuing research into the mechanisms of cancer cell 
dormancy could result in a treatment that would prevent 
cancer cell proliferation in the bone and the chain of 
events that leads to osteolysis.
Since the discovery of RANKL and its role in bone 
remodeling, the ﬁ   eld of bone metastasis has moved 
rapidly. It is now generally accepted that the bone 
microenvironment is critical to the colonization and 
growth or dormancy of metastases. Nevertheless, the 
inaccessibility, opacity and size of the skeleton make it 
diﬃ   cult to study even in laboratory animals. Commonly, 
human cancer cells are studied as xenografts in 
immunodeﬁ  cient mice, or rodent tumors are studied in 
syngeneic models. However, more accessible and deﬁ  ned 
[76] models are needed. Several groups have developed 
in vivo models in which bone or bone substitutes are 
implanted in animals. Retrieval of the bone at speciﬁ  c 
times gives a snapshot of the status of metastases. For 
example, a hydroxyapatite scaﬀ  old pre-loaded with bone 
morphogenetic protein-2 enhanced the growth rate of 
mammary tumor cells in the scaﬀ  old [77]. Fragments of 
human fetal bone implanted in SCID mice allow one to 
examine human cancer with human bone [76]. Th  ese 
approaches still rely on animals. Recently we have begun 
developing an in vitro bioreactor [78]. Using this device, 
we have been able to grow osteoblasts into a mineralized 
tissue. Metastastic human breast cancer cells 
(MDA-MB-231) added to this culture attach, penetrate 
the tissue and form single cell ﬁ   les characteristic of 
metastases seen in pathologic tissues. Th  e cancer cells 
aﬀ   ect osteoblast morphology and extracellular matrix. 
We are in the process of adding osteoclasts to the system 
to create a rudimentary in vitro bone remodeling unit. 
Th   is approach will allow testing of components and drugs 
in a model less complex than an animal but more relevant 
than standard tissue culture.
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